Alexion Pharmaceuticals is acquiring Achillion Pharmaceuticals for $930 million, a deal that could strengthen its position providing treatments for a rare blood disorder.
According to financial terms announced Wednesday, Boston-based Alexion... Read more »
Cyteir Therapeutics has $40.2 million more in cash to support early-stage tests of a drug intended to treat cancer by targeting a tumor repair mechanism.
The new cash that Cyteir announced... Read more »
Eli Lilly won FDA approval for a migraine drug on Friday, giving the pharmaceutical giant a second medication that addresses the condition that causes millions of people to experience severe headaches... Read more »
Vir Biotechnology has joined the public markets, raising $142.9 million to support clinical tests of its infectious disease drugs.
The San Francisco firm offered 7.1 million shares priced at $20 each,... Read more »
Ra Pharmaceuticals, whose lead autoimmune disease drug candidate is viewed as a potential alternative to one of the most expensive medicines in the world, is being acquired by Belgian pharmaceuticals giant... Read more »
The peripheral nervous system traverses the body, connecting the brain and spinal cord to distant organs and limbs similar to the way a fiber optic network connects an Internet provider to... Read more »
Oxygen’s importance in cellular processes has long been known. But the work to understand how cells sense and adapt to changes in oxygen levels has led to medical insights and potential... Read more »
With five biotech IPOs on the calendar, this week was expected to be a big one. Three companies ended up making Wall Street debuts, raising a combined $320 million, led by... Read more »
Many vaccines are made from either a weakened virus or a protein taken from a virus. But so far, scientists haven’t had much luck developing such vaccines for respiratory syncytial virus... Read more »
[Updated 5:58 p.m. PT. See below.] Organovo, a company developing technology to 3D print human tissue, announced two months ago that its dwindling cash is leading it to explore... Read more »
Michael Ehlers, Biogen’s executive vice president of research and development, is leaving for a job in venture capital and an opportunity to lead a gene therapy startup.
Ehlers has been appointed... Read more »
In the past three years, Dova Pharmaceuticals has completed a company launch, gone public, and won its first drug approval. Now the biotech is in line to be acquired by Swedish... Read more »
A number of gene-editing companies have joined the public markets in recent years. Beam Therapeutics, which is developing a CRISPR-based technology intended to offer even more precise genomic edits, aims to... Read more »
Lung injuries linked to electronic cigarettes have topped 800 cases, including 12 deaths, according to the Centers for Disease Control and Prevention. Public health officials aren’t sure whether the injuries... Read more »
Akcea Therapeutics has already been struggling to turn its two products into commercial winners. Now it will have to do so during a massive management transition.
Akcea (NASDAQ: AKCA) said... Read more »
Ivan Liachko turned postdoctoral research at the University of Washington into a company whose genomics tools are now found in laboratories researching human, animal, and plant health. His firm, Phase Genomics,... Read more »
Ginkgo Bioworks, a synthetic biology specialist that has become worth billions, has raised another $290 million to expand the breadth of a technology that tinkers with a cell’s genetic code and... Read more »
A panel of independent advisors to the FDA voted on Friday to recommend approval of an experimental peanut allergy drug from Aimmune Therapeutics. But concern about the risks of an... Read more »
Add another once-promising Alzheimer’s disease drug to the scrap heap.
Eisai and Biogen (NASDAQ: BIIB) are halting a Phase 3 test after an independent safety review concluded the risks of... Read more »
Wall Street welcomed three life science companies to the public markets this week. 10x Genomics led the way Wednesday, followed by SpringWorks Therapeutics and Satsuma Pharmaceuticals on Thursday. Combined, the three... Read more »